B-VEC, a replication-defective HSV-1 vector designed to restore functional C7 protein through the delivery of functional COL7A1, can treat wounds in patients 6 months or older with dystrophic epidermolysis bullosa caused by COL7A1 mutations (Table 4) [39, 232, 233]. This evidence concerns the gene COL7A1 and epidermolysis bullosa.